

MIXED LYMPHOCYTE CULTURE DETERMINANTS AND C2 DEFICIENCY: LD-7a ASSOCIATED WITH C2 DEFICIENCY IN FOUR FAMILIES*

By S. M. FU, R. STERN,‡ H. G. KUNKEL, B. DUPONT, J. A. HANSEN,§ N. K. DAY,||
R. A. GOOD, C. JERSILD, AND MARILENA FOTINO

(From The Rockefeller University, Sloan-Kettering Institute for Cancer Research, and the New York
Blood Center, New York 10021)

Recent studies (1, 2) have demonstrated a genetic linkage between the HL-A system of the major histocompatibility complex (MHC)¹ and deficiency of the second component of complement (C2). In the first case studied (1) the proband who was homozygous for C2 deficiency also was homozygous for the HL-A haplotype 10,W18. The latter subsequently has been encountered in association with C2 deficiency in three additional families (2, 3), an extraordinary incidence as compared to that in the general population. In addition, however, several other HL-A haplotypes have been encountered. The present studies were carried out to document these relationships further with particular emphasis on studies with mixed lymphocyte culture (MLC) reactions to determine the MLC genes involved and to map the location of the C2 gene in relation to the MHC.

Methods and Materials

Serum samples were obtained from clotted blood, quickly frozen, and stored at -60°C . Samples were thawed once. C2 determinations for members of the C and G families were performed by radial immunodiffusion. In addition, the C2 level of the proband from family C was also measured by hemolytic titration (4). The heterozygous individuals were recognized by their level of C2 which was close to one-half of the normal. The levels of C2 in members of the S and K families were reported previously (1, 2).

HL-A typing was done either by a two-stage microcytotoxicity assay procedure (1) or a one-stage assay method (2). Unidirectional mixed leukocyte cultures were performed by two methods. Method A is a slight modification of the procedure described by Hartzman et al. (5). Briefly, lymphocytes were isolated by Ficoll-Hypaque gradient centrifugation. 1.5×10^6 X-irradiated (3,000 rad) stimulating and 1.5×10^5 responding cells in a total vol of 0.2 ml of RPMI 1640 medium supplemented with streptomycin, penicillin, and 20% heat-inactivated normal human serum were

*This investigation has been supported by U. S. Public Health Service grants AI-10811, AI-11843-02, NCI-CA 17404-01, and NCI 08748-10; and RR-102 from the National Institutes of Health.

‡ Supported by a NIH postdoctoral fellowship.

§ Special fellow of The Leukemia Society of America.

|| Established investigator of the American Heart Association.

¹Abbreviations used in this paper: C2, second component of complement; LD, lymphocyte-defined; MHC, major histocompatibility complex; MLC, mixed lymphocyte culture; RR, relative response; SR, stimulation ratio.

mixed in the wells of Falcon microtiter plates (Falcon Plastics, Div. of BioQuest, Oxnard, Calif.). Each culture was set up in triplicate. After 6 days of incubation at 37°C in 5% CO₂ humidified atmosphere, 2 μCi of [³H]thymidine was added to each culture 16 h before harvesting. The lymphocytes were harvested and processed for liquid scintillation counting. Method B is a procedure reported by Jørgensen and Lamm (6). Briefly, lymphocytes were isolated by Lymphoprep (Nyegard, Oslo) gradient centrifugation; 5 × 10⁴ responding lymphocytes and 5 × 10⁴ stimulating lymphocytes were cultured in a final vol of 150 μl in RPMI 1640 medium supplemented with bicarbonate, Hepes buffer, streptomycin, penicillin, heparin, glutamine, and 15% pooled, normal human serum. The stimulating lymphocytes were X-inactivated by 1,250 rad total irradiation (125 rads per minute). The cultures were performed in plastic microtiter plates (no. 1-221-24-1, Cooke Laboratory Products, Alexandria, Va.) and were set up in triplicates. After 120 h of incubation at 37°C in 5% CO₂ humidified atmosphere, the cultures were labeled with 0.025 μCi of [2-¹⁴C] thymidine in 25 μl RPMI 1640 ([2-¹⁴C]thymidine, spec act 50 mCi/mmol, New England Nuclear, Boston, Mass.). After 24 h of additional culture, the lymphocytes were harvested on Whatman glass filter paper GF/C and processed for liquid scintillation counting.

Results of MLC testing are expressed as the mean of triplicate cultures in counts per minute (cpm). Stimulation ratios (SR) are calculated from the formula $SR(A) = ABx/AAx$. Relative response (RR) is calculated from the formula $RR(A) = (ABx - AAx)/(Reference Response - AAx)$, where Reference Response is the response of A against an unrelated normal control or control pool (7). Application of lymphocyte-defined (LD) homozygous test cells (LD typing cells) as stimulating cells in the MLC test to define LD specificities demonstrate that the responses obtained fall into two distinct groups: (a) Individuals who do not carry the LD specificity defined by the LD typing cell: RR 36% - >100% and (b) Individuals carrying the LD specificity defined by the LD typing cell: RR 0-35%. This last group can be subdivided into a group expressing relative MLC identity: RR 0-10% and another group defining "LD-likeness" with RR 11-35%.

SD and LD Homozygous Test Cells. 12 LD homozygous test cells were included in the study. The panel of typing cells represent MLC determinants with a cumulated gene frequency of 0.718. The test cells included the common LD specificities LD-7a, LD-8a, LD-W5a, LD-12a, LD-W15a which are in genetic linkage disequilibrium with the FOUR locus serologically defined antigens HL-A 7, 8, W5, 12, and W15.² The LD-7a homozygous test cell (CM) is HL-A 3,7 homozygous, and mutually nonresponsive in MLC test with the original LD-7a test cells (Histocompatibility Workshop, Copenhagen, 1975, no. 12003) (8). The LD-7a gene frequency in the North American Caucasian population is 0.11. The same LD specificity has a gene frequency of 0.10 in the Dutch population (9) and 0.096 in the Danish population (10). The LD-7a determinant is in genetic linkage disequilibrium with the FOUR locus antigen HL-A7 (11), the Δ-value being 0.036 (10) and 0.077 (9).

Results

Families with C2 Deficiency. The S family was the first family where studies showed the linkage between HL-A histocompatibility genes and those involved in the synthesis of C2 (1). A part of the S family is shown in Fig. 1 a. The propositus, L. S. is homozygous for C2 deficiency and the HL-A 10,W18. Similar linkage was also found in the large K family (2). In Fig. 1 b, a part of the K family is depicted. The propositus, R. K., is homozygous for C2 deficiency but heterozygous for the HL-A haplotypes 2,4A2* and 10,W18. After these initial studies, two additional Caucasian families, C and G, have recently been encountered at The Rockefeller University, New York. Their pedigrees are depicted in Fig. 2. The propositus, J. C. in family C, is a woman with discoid lupus erythematosus who is homozygous for C2 deficiency. Clinical details of this case will be reported elsewhere (4). The propositus is heterozygous for the HL-A haplotypes 9,5 anf 10,W18. She obtained

² Hansen J. A., B. Dupont, L. Slater, R. A. Good, C. Jersild, M. Fotino, P. Rubinstein, F. Allen, N. Suiciu-Foca, E. Mickelson, D. L. Thomas, S. M. Fu, and H. G. Kunkel. 1975. VI International Histocompatibility Workshop, 1975. In preparation.




FIG. 1. Parts of pedigrees of (a) Family S and (b) Family K. The heterozygous and homozygous C2-deficient cases are indicated by the solid black symbols and the HL-A type is given in adjacent space.




FIG. 2. (a) The pedigree of Family C and (b) the pedigree of Family G. The heterozygous and homozygous C2-deficient cases are indicated by the solid black symbols and the HL-A type is given in adjoining space. The HL-A assignment for I₁ and I₂ in Family C were made from the typing results of their family members and are indicated by double asterisks.

the HL-A haplotype 10,W18 from her mother. The father is unavailable for typing. There is no history of consanguinity. The proband in the G family is healthy and heterozygous for C2 deficiency. Her father and her son are also heterozygous for C2 deficiency. In this family, the gene for C2 deficiency appears to be linked to the HL-A haplotype 10,W18.

Identical MLC Locus Associated with C2 Deficiency. As reported previously (1) the proband, L. S. of the S family, is homozygous for the MLC (LD) locus. A part of the S family pedigree relevant to this discussion is shown in Fig. 1 a and the MLC homozygosity of L. S. is documented in Table I. L. S. failed to

stimulate the cells of her children G. S. and C. D., while here childrens' cells stimulated her cells well.

Although the propositus, J. C., in the C family, is heterozygous for the loci of the HL-A system, she is homozygous for the MLC locus as shown in Table II. None of her three children responded to her cells while she responded to their cells. MLC homozygosity of J. C. is also shown in the MLC reactions between her children, K. C. and M. C. Both K. C. and M. C. inherited the same HL-A haplotype 3,7 from their father, F. C. Although they inherited different HL-A haplotypes from their mother, J. C., they were nonreactive in MLC. This indicates that identical MLC determinants are associated with the HL-A haplotypes 9,5 and 10,W18. In addition, J. C. (from the family C) and L. S. from the family S were mutually nonreactive in MLC.

In the family K(2), the propositus R. K., as shown in Fig. 1 b, is heterozygous for the HL-A loci. In Table III is shown the results of MLC testing performed

TABLE I
MLC* Reactions Among Members of the S Family Showing the Propositus, L. S., to be Homozygous

Responding cells: HL-A genotypes	Stimulator cells							
	L. S. x		A. S. x		G. S. x		C. D. x	
	cpm‡	SR§	cpm	SR	cpm	SR	cpm	SR
L. S. , (mother): 10,W18/10,W18	(238)	—	10,834	45	25,343	108	9,575	40
A. S., (father): 11,12/3,5	5,491	11	(485)	—	47,229	97	24,606	50
G. S., (child): 3,5/10,W18	1,351	1	64,090	33	(1,922)	—	75,835	39
C. D., (child): 11,12/10,W18	2,660	2	61,673	41	71,423	48	(1,501)	—

* MLC reactions were carried out by Method A.

‡ cpm indicates the means of cpm of triplicate samples.

§ SR is the stimulation ratios (ABx/AAx) and is expressed as the nearest integer.

|| Indicates homozygous C2 deficiency.

TABLE II
MLC* Reactions Among Members of the C Family and L. S. Showing J. C., the Propositus, Homozygous and MLC Identical to L.S.

Responding cells: HL-A genotypes	Stimulator cells											
	L. S. x		J. C. x		F. C. x		K. C. x		S. C. x		M. C. x.	
	cpm‡	SR§	cpm	SR	cpm	SR	cpm	SR	cpm	SR	cpm	SR
L. S. §: 10,W18/10,W18	(1,039)	—	1,259	1	21,588	21	17,184	17	8,188	8	4,782	5
J. C. § (mother): 9,5/10,W18	1,065	2	(689)	—	25,131	36	16,556	24	19,302	28	15,139	22
F. C. (father): 3,7/2,W22	26,614	67	29,760	75	(397)	—	31,981	81	31,494	79	23,972	60
K. C. (child): 3,7/10,W18	1,514	3	1,941	3	23,972	40	(602)	—	30,240	50	1,077	2
S. C. (child): 2,W22/9,5	1,159	2	946	1	15,909	22	20,064	28	(714)	—	18,780	26
M. C. (child): 3,7/9,5	1,671	2	629	1	33,254	47	3,955	6	54,872	78	(702)	—

* MLC reactions were carried out according to Method A.

‡ See Table I.

§ Indicates homozygous C2 deficiency.

TABLE III
MLC* Reactions of Members of the K Family and L. S. Showing the Propositus, R. K., Homozygous, and MLC Identical to L. S.

Responding cells: HL-A genotypes	Stimulating cells																				
	L. S. x		R. K. x		Ro. K. x		L. K. x		Rt. K. x		Rh. K. x		Ri. K. x								
	cpm	SR RR	cpm	SR RR	cpm	SR RR	cpm	SR RR	cpm	SR RR	cpm	SR RR	cpm	SR RR							
L. S. †: 10, W18/10, W18	(164)	—	—	607	4	8	3,530	22	61	3,450	22	60	2,852	17	48	3,701	23	63	3,896	24	66
R. K. ‡ (child): 2, 4A2*/10, W18	334	2	3	(143)	—	—	2,529	18	42	2,437	17	40	2,833	20	47	4,512	32	77	3,393	24	57
Ro. K. (father): 2, 4A2*/2, 13	1,897	6	22	445	1	1	323	—	—	4,069	13	44	547	2	2	5,037	16	55	5,220	16	57
L. K. (mother): 10, W18/2, W27	2,240	6	29	592	2	3	3,773	9	54	(403)	—	—	3,427	9	48	2,440	6	33	1,665	4	20
Rt. K. (child): 2, 13/10, W18	1,980	11	18	820	5	7	364	2	2	3,748	22	36	167	—	—	4,737	28	46	4,080	24	40
Rh. K. (child): 2, 13/2, W27	3,622	24	53	3,138	22	45	4,185	29	61	2,436	24	35	4,052	28	59	143	—	—	4,181	29	61
Ri. K. (child): 2, 4A2*/2, W27	3,039	2	31	1,016	1	0	4,255	3	57	1,126	1	0	3,689	2	21	3,599	2	42	1,556	—	—

RR ≤ 35% obtained with LD homozygous test cells indicate typing responses.

* MLC reactions were done by Method B.

† Indicates homozygous C2 deficiency.

TABLE IV
MLC* Responses among Members of the G Family and L. S. Showing that those Family Members with HL-A 10, W18 Share Similar MLC Determinants with L. S.

Responding cells: HL-A genotypes	Stimulating cells													
	L. S. x		A. G. x		R. G. x		N. G. x		M. G. x		E. G. x		P. G. x	
	cpm ‡	SR ‡	cpm	SR	cpm	SR	cpm	SR	cpm	SR	cpm	SR	cpm	SR
L. S. †: 10, W18/10, W18	(208)	—	10,637	51	12,268	59	7,174	34	9,067	43	16,165	77	3,425	16
A. F. (grandfather): 1, W5/10, W18	2,330	7	(337)	—	12,279	36	11,620	34	11,784	34	37,139	110	8,624	26
R. G. (grandmother): 2, W5/3, 12	31,704	64	24,743	50	(493)	—	1,488	5	23,333	49	41,466	84	23,332	68
N. G. (maternal aunt): 1, W5/3, 12	25,094	37	17,555	26	1,545	2	(679)	—	17,342	26	37,145	55	16,917	25
M. G. (mother): 10, W18/3, 12	3,469	7	17,886	38	21,521	46	23,840	51	(471)	—	36,298	77	10,644	23
E. G. (father): 9, W16/W19, —	34,877	17	60,801	30	50,144	25	45,128	22	39,055	19	(2,011)	—	24,613	12
P. G. (child): 9, W16/10, W18	1,248	3	12,456	40	14,521	47	15,586	51	7,902	26	11,050	36	(306)	—

* MLC reactions were carried out by Method A.

† See Table I.

‡ Indicates homozygous C2 deficiency.

TABLE V
MLC* Reactions of C2-Deficient Homozygotes

Responding cells		Stimulator cells								
		C. M. x			L. S. x			R. K. x		
HL-A genotypes	LD-genotype	cpm‡	SR‡	RR‡	cpm	SR	RR	cpm	SR	RR
C. M.: 3,7/3,7	7a/7a	(212)	—	—	1,656	7.8	13	2,346	11.1	20
L. S.‡: 10,W18/10,W18		314	2.3	2	(134)	—	—	707	5.3	7
R. K.‡: 2,4A2*/10,W18		1,172	9.3	14	823	6.5	9	(126)	—	—
J. C.‡: 9,5/10,W18		471	4.7	4	375	3.8	3	170	1.7	0
M. T.: 9,7/1,TY	7a/Un¶	2,404	4.6	19	4,369	8.8	41	1,840	3.5	13
T. K.: 3,7/1,8	7a/8a	937	2.1	4	3,546	8.0	27	3,792	8.6	29
E. S.: 1,2,W5,W18	7a/Un	628	3.1	4	1,696	8.5	15	802	4.0	6
B. D.: 2,10,5,MK	Un/Un	8,398	23.2	84	4,459	12.3	42	4,438	12.3	42

* MLC reactions were done by Method B.

‡ See Table III.

§ "Pool" indicates a pool of cells from four unrelated individuals.

|| Indicates homozygous C2 deficiency.

¶ Un indicates unknown LD genotypes which are not 7a.

between the family members of family K and the C2-deficient patient L. S. (family S). The lymphocytes of L. S. and of the propositus R. K. (family K) are mutually nonresponsive in MLC tests. L. S. and R. K. do not stimulate the lymphocytes from family members in family K with the HL-A haplotypes 2,4A2* and 10,W18. These family members are also heterozygous for C2 deficiency. The C2 normal family member Rh. K., who has inherited the other two parental HL-A haplotypes 2,13 and 2,W27, shows a normal MLC response when stimulated by the cells of L. S. and R. K. Proof of the LD homozygosity of the R. K. cells is given by the MLC combinations Ro. K. × Ri. K. (2,4A2*/2,13 × 10,W18/2,13) and by the combinations L. K. × Ri. K. (10,W18/2,W27 × 2,4A2*/2,W27).

In the other C2-deficient family, i.e. family G, the propositus is heterozygous for HL-A loci and C2 deficiency. The members of the G family stimulated L. S. cells well (Table IV). However, those with the HL-A haplotype 10,W18 (A. G., M. G., and P. G.) failed to respond to L. S. in the MLC reaction while the other three members of the family responded well.

Thus, it appears that the three C2-deficient homozygous individuals from different families are mutually nonreactive in MLC and the C2-deficient heterozygotes did not respond to the cells of the C2-deficient homozygotes. This point is further documented in a separate experiment shown in Table V. Here it is shown that the MLC gene associated with the C2 deficiency gene is LD-7a. In this experiment, values for the responses were calculated as RR. The cells from the three C2-deficient homozygotes and a known LD-7a homozygote, CM without C2 deficiency, were mutually nonreactive. In this testing lymphocytes from three known LD-7a heterozygous individuals with normal C2 levels (M. T., T. K., and E. S.) were included. The lymphocytes from the three homozygous C2-deficient patients (L. S., R. K., and J. C.) functioned as LD homozygous test cells when stimulating the LD-7a heterozygous cells, and the mutual MLC identity between the three cells and the LD-7a homozygous test cell (CM) identified the LD-7a determinant as the appropriate LD specificity. The three C2 homozygous cells did not show typing responses with LD homozygous test cells

(L. S., R. K., J. C.) and 7a and non 7a Individuals

Stimulator cells														
J. C. x			M. T. x			T. K. x			B. D.			Pool§ x		
cpm	SR	RR	cpm	SR	RR	cpm	SR	RR	cpm	SR	RR	cpm	SR	RR
639	3.0	4	9,894	46.7	92	5,842	27.6	53	8,187	38.6	76	10,665	50.3	100
259	1.9	1	6,275	46.8	81	2,006	15.0	24	7,246	54.1	94	7,690	57.4	100
322	2.6	2	4,745	37.7	99	3,160	25.1	41	5,391	42.8	71	7,466	59.3	100
(100)	—	—	6,918	69.2	84	4,187	41.9	50	6,845	68.5	83	8,165	81.7	100
2,808	5.4	23	(519)	—	—	5,280	10.2	48	9,471	18.2	91	10,295	19.8	100
2,308	5.2	16	11,951	27.0	102	(442)	—	—	12,827	29.0	110	11,694	26.5	100
1,351	6.8	12	8,211	41.0	82	6,900	34.5	69	9,410	47.0	95	9,895	49.5	100
6,125	16.9	60	10,236	28.3	103	10,974	30.3	111	(362)	—	—	10,155	28.1	100

other than the LD-7a. The relative response of 41% by the LD-7a heterozygous cells from M. T. when they were stimulated by the L.S. cells, was the only discordant observation. The L. S. cells have been included as an L. D. homozygous test cell to stimulate a panel of randomly selected normal Caucasian blood donors in New York City. Of 42 individuals tested so far, seven showed typing responses to the test cells, giving a gene frequency of 0.087. This is a slightly lower gene frequency than the one for the LD-7a test cell (0.110). The studies seem to indicate that the L. S. test cell may express minor LD inclusions on the major LD locus in addition to the LD-7a specificity (12).

Cross-over Between the HL-A Loci and the C2 Gene. HL-A and LD typing of the family members in family C (Fig. 2 a) together with C2 level determinations seem to supply additional information concerning the mapping of the C2 gene in relation to the MHC. The mother (J. E.) of patient J. C. is C2 heterozygous. Her two siblings H. B. (10,W18/1,W17) and W. L. (W19,W18/1,W17) have normal C2 levels. They are mutually nonreactive in MLC testing and do not carry the LD-7a determinant as shown by the vigorous response to the LD-7a test cell (CM) and to the lymphocytes from the two C2 homozygous deficient patients L. S. and J. C. (Table VI).

Their sister J. E., who has the HL-A haplotype 10,W18 in common with H. B., does carry the LD-7a determinant on one haplotype. The positive MLC response of the LD-7a test cell (CM) to her lymphocytes demonstrate, however, that J. E. is LD-7a heterozygous. Her diseased child J. C. does not respond to the stimulation of the maternal cells. The observation that the two siblings H. B. and W. L. are mutually nonresponsive in MLC, together with the above observation, indicates that the two MHC haplotypes 10,W18 and W19,W18 must have some LD components in common but differ on others. Thus, H. B. might represent a recombinant, but less likely possibilities could be considered.

Discussion

Four C2-deficient families from different geographic locations and with diverse national origins were studied in this investigation. The proposita from three

TABLE VI
Additional MLC Responses Among Some Members of the C Family and 7a Individuals, Showing the Reaction of H. B. a Possible Recombinant of MLC and HL-A Loci*

Responding cells: HL-A genotype	Stimulating cells													
	L. S. x		C. M. x		J. C. x		J. E. x		H. B. x		W. L. x		R. S. x	
	cpm†	SR‡	cpm	SR	cpm	SR	cpm	SR	cpm	SR	cpm	SR	cpm	SR
L. S.§ : 10, W18/10, W18	(157)	—	367	1	174	1	3,295	21	6,347	40	3,449	22	3,971	25
C. M. : 3,7/3,7	1,420	2	(713)	—	1,910	3	61,928	87	85,962	120	77,390	108	55,409	78
J. C.§ (child): 9,5/10, W18	248	1	574	1	(443)	—	1,870	4	11,420	26	6,638	15	7,673	17
J. E. (mother): 10, W18/W19, W18	619	2	7,431	19	1,126	3	(390)	—	17,737	45	8,490	22	12,966	33
H. B. (aunt): 10, W18/1, W17	16,114	52	109,002	352	41,558	133	21,833	71	(309)	—	437	1	17,379	56
W. L. (uncle): 1, W17/W19, W18	17,379	31	89,588	163	32,236	59	14,962	27	678	1	(548)	—	16,556	30
R. S.¶ (unrelated)	12,226	21	100,119	170	31,080	53	24,908	42	24,964	42	16,726	28	(588)	—

* MLC reactions were done by Method A.

† See Table I.

§ Homozygous C2 deficiency.

|| Homozygous LD-7a individuals and CM is a 7a homozygous test cell (Histocompatibility Workshop Cell HWC no. 3001) which is mutually nonresponsive with the original 7a-test cell HWC no. 12003.

¶ His HL-A typing shows HL-A 3,10,W5,W16.

families are homozygous for C2 deficiency and those of the fourth family are heterozygous for C2 deficiency. HL-A typing studies of these families reveal that the haplotype 10,W18 is encountered in all four individuals. Since one of them (L. S.) is homozygous for the HL-A haplotype 10,W18, this haplotype is present in five instances. Other HL-A haplotypes encountered in these families associated with C2 deficiency are HL-A 9,5, HL-A 2,4A2*, and HL-A2, W18 (1-3). The haplotype HL-A 10,W18 has a gene frequency of less than 1% (13). The prominence of this haplotype in association with C2 deficiency appears to represent a remarkable linkage disequilibrium between these two loci. The more accurate estimate of this phenomenon will be available as more C2-deficient families are being typed for HL-A antigens.

Family studies in MLC reactions indicate that the MLC locus is even more closely linked to the genes of C2 deficiency. Particularly striking was the finding that the three C2-deficient homozygotes of the three families were mutually nonreactive in the MLC reactions. In addition, the heterozygous C2-deficient individuals in the fourth family were nonreactive to the stimulation by the one of these homozygotes tested. Thus, these data indicate that the seven MHC involved in the C2 deficiency of the four families possess an apparently identical MLC gene. Further MLC typing experiments revealed that LD-7a is involved in all these instances. LD-7a is relatively common in the Caucasian population with a gene frequency of 0.11 in the North American Caucasian population and is in positive genetic linkage disequilibrium with the FOUR locus antigen HL-A7 (9-11). The exact gene frequency of C2 deficiency in the Caucasian population is not known but it is reasonable to assign an estimate of 0.01-0.02 (14). Thus, the association of LD-7a with C2 deficiency also appears to show linkage disequilibrium. More family studies are needed to determine if other LD determinants are involved in C2 deficiency.

The association of LD-7a with C2 deficiency in these families deserves further comment. This MLC determinant has been shown to be associated with patients with multiple sclerosis (15). Furthermore, the patients with multiple sclerosis have some suppression of cell-mediated immunity (16, 17). The three homozygotes in this study have manifestations of systemic lupus erythematosus (SLE). It is relevant that similar suppression of cell-mediated immunity has also been demonstrated in SLE (17). Perhaps, the associated immune response genes predispose these homozygotes to have the lupus erythematosuslike syndrome and possibly healthy homozygotes with C2 deficiency might possess different immune response genes. As further studies involving these C2-deficient individuals progress, a clear answer to this questions should be obtained.

One individual of the C family in these studies might represent a recombinant within the MLC locus and the C2 gene. She has the HL-A haplotype 10,W18, associated with C2 deficiency in other members of this family, but she is neither LD-7a nor a C2-deficient individual. This finding would place the genes governing C2 deficiency close to the LD genes which have been placed outside the second and the first HL-A locus. As reported in previous studies (2), an additional possible recombinant between the FOUR and C2-deficient loci is found in the K family. If this is indeed the case there are two recombinants resulting from 50 meiotic events in the four families and the recombination frequency between the FOUR HL-A locus and that of C2 deficiency is approximately 4%. This frequency is ex-

traordinarily high in view of the marked linkage disequilibrium between these two loci. The reasons for this paradoxical phenomenon are obscure. It is estimated that the recombination frequency between the FOUR HL-A locus and the major MLC locus is less than 1% (18). These very preliminary and indirect estimations would suggest placing the locus governing C2 deficiency outside the major MLC locus as well as the HL-A loci. One of the chromosomes encountered in this study would have the relevant genes in the following order: C2 deficiency, 7a, W18, HL-A10; the genes of the major histocompatibility complex and C2 deficiency on chromosome 6 might be assigned the following order: C2 deficiency, MLC (major), HL-A (FOUR locus), HL-A (LA locus). Further studies certainly are required to substantiate these relationships.

In addition to C2 deficiency, the locus for factor B of the alternate complement pathway is closely linked to the HL-A histocompatibility locus (19). In this case, the structural gene for factor B is probably involved. Although it is likely that C2 deficiency results from some structural gene alteration involving the C2 gene itself, the possibility still remains that a regulator or another gene defect in the synthetic pathway of C2 might be involved. In the mouse, the accumulated evidence suggests that the *S* region in the *H-2* complex controls complement activity either directly by containing the structural gene for one or more components or indirectly by a regulatory pathway (20). Serum C3 levels have been shown to vary from strain to strain and the gene responsible for this variation is linked to the *H-2* complex (21). The possibility also exists that the *Ss* protein of the mouse determined by the *S* region is itself a complement component (22). Evidence exists that it is not C3 or Factor B. However, the possibility that it might represent C2 remains open. The positioning of the C2 deficiency gene mentioned above is not directly parallel to the *Ss* position of the mouse but there are a number of known differences in this genetic region between the mouse and human genes (18).

Summary

Four families with C2 deficiency were studied. Among eight HL-A haplotypes involved with C2 deficiency, five were HL-A 10,W18. Three homozygotes for C2 deficiency from different families were mutually nonreactive in mixed lymphocyte cultures (MLC) and the heterozygotes from the fourth family failed to react to the homozygous cells. It appeared that identical MLC determinants were associated with all the genes from the different families that related to C2 deficiency. Further experiments identified the MLC determinant, LD-7a, as being involved. These results suggest marked linkage disequilibrium between the genes for C2 deficiency and the major histocompatibility complex (MHC). Studies of possible recombinants have offered tentative evidence for the positioning of the locus for C2 deficiency with respect to other segments of the MHC.

We acknowledge the excellent technical assistance of Ms. Ruth Brooks, F. Joslin, S. Feuerstein, S. Jaramillo, P. Onasis, J. Blank, and Mr. C. Craig.

Received for publication 8 May 1975.

Note added in proof: Two additional families with C2 deficiency subsequently have been studied. In one instance the C2 deficiency was not associated with LD-7a. Thus, in a total of six families, five showed the association.

References

1. Fu, S. M., H. G. Kunkel, H. P. Brusman, F. H. Allen Jr., and M. Fotino. 1974. Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement. *J. Exp. Med.* **140**:1108.
2. Day, N. K., P. L'Esperance, R. A. Good, A. F. Michael, J. A. Hansen, B. Dupont, and C. Jersild. 1975. Hereditary C2 deficiency: genetic studies and association with the HL-A system. *J. Exp. Med.* **141**:1464.
3. Fu, S. M., and H. G. Kunkel. 1975. Association of C2 deficiency and the HL-A haplotype 10,W18. *Transplantation*. In press.
4. Stern, R., S. M. Fu, V. Agnello, M. Fotino, and H. G. Kunkel. 1975. Hereditary C2 deficiency: association with skin lesion resembling discoid lesion of SLE. *Arthritis Rheum.* In press.
5. Hartzman, R. J., M. Segall, M. L. Bach, and F. H. Bach. 1971. Histocompatibility matching. VI. Miniaturization of the mixed leukocyte culture test: a preliminary report. *Transplant. Bull.* **2**:268.
6. Jörgensen, F., and L. U. Lamm. 1974. MLC—A Micro Modification of the Mixed Leucocyte Culture Technique. *Tissue Antigens.* **4**:482.
7. L'Esperance, P., J. A. Hansen, C. Jersild, R. O'Reilly, R. A. Good, M. Thomsen, L. S. Nielsen, A. Svejgaard, and B. Dupont. 1975. Bone marrow donor selection among unrelated FOUR-locus identical individuals. *Transplant. Proc.* **7**(Suppl. 1):823.
8. Dupont, B., R. A. Good, G. S. Hansen, Jersild, L. S. Nielsen, B. H. Park, A. Svejgaard, M. Thomsen, and E. J. Yunis. 1974. Two separate genes controlling stimulation in mixed lymphocyte reaction in man. *Proc. Natl. Acad. Sci. U.S.A.* **71**:52.
9. Keuning, J. J., A. Termigtelen, A. B. van Oud, Alblas, J. G. Tweel, I. Schreuder, and J. J. van Rood. 1975. Typing for MLC (LD). *Transplant. Proc.* **7**:Suppl. 1:35.
10. Thomsen, M., P. Platz, O. O. Andersen, M. Christy, J. Lyungso, J. Nerup, V. Rasmussen, L. P. Ryder, L. S. Nielsen, and A. Svejgaard. 1975. MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. *Transplant. Rev.* **22**:125.
11. Dupont, B., C. Jersild, G. S. Hansen, L. S. Nielsen, M. Thomsen, and A. Svejgaard. 1973. Typing for MLC determinants by means of LD-homozygous and LD heterozygous test cells. *Transplant. Proc.* **5**:1543.
12. Dupont, B., C. Jersild, G. S. Hansen, L. S. Nielsen, M. Thomsen, and A. Svejgaard. 1973. Multiple MLC (LD) determinants on the same HL-A haplotype. *Transplant. Proc.* **5**:1481.
13. Allen, F., D. B. Amos, R. Batchelor, W. Bodmer, R. Ceppellini, J. Dansset, C. Engelfriet, M. Jeannet, F. Kissmeyer-Nielsen, P. Morris, R. Payne, P. Terasaki, J. J. van Rood, R. Walford, C. Zmijewski, E. Albert, P. Mattius, M. R. Mickey, and A. Piazza. 1970. Joint Report of Fourth International Histocompatibility Workshop. Histocompatibility Testing, 1970. Munksgaard, A/S, Copenhagen, Denmark.
14. Agnello, V., M. M. E. de Bracco, and H. G. Kunkel. 1972. Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus. *J. Immunol.* **108**:873.
15. Jersild, C., T. Fog, G. S. Hansen, M. Thomsen, A. Svejgaard, and B. Dupont. 1973. Histocompatibility determinants in multiple sclerosis with special reference to clinical course. *Lancet* **2**:1221.
16. Utermohlen, V., and J. Zabriskie. 1973. A suppression of cell-mediated immunity in patients with multiple sclerosis. *J. Exp. Med.* **138**:1591.
17. Utermohlen, V., J. B. Winfield, J. B. Zabriskie, and H. G. Kunkel. 1974. A depression of cell-mediated immunity to measles antigen in patients with systemic lupus erythematosus. *J. Exp. Med.* **139**:1019.
18. Thorsby, G. The human major histocompatibility system. 1974. *Transplant. Rev.* **18**:51.

19. Allen, F. H. Jr. Linkage of HL-A and GBG. 1974 *Vox Sang.* **27**:382.
20. Demant, P., J. Capkova, E. Hinzova, and B. Voracova. 1973. The role of the histocompatibility 2-linked Ss-Slp region in the control of mouse complement. *Proc. Natl. Acad. Sci. U.S.A.* **70**:863.
21. Ferreira, A., and V. Nussenzweig. 1975. Genetic linkage between serum levels of the third component of complement and the *H-2* complex. *J. Exp. Med.* **141**:513.
22. Hansen, T. H., Hyun S. Shin, and Donald C. Shreffler. 1975. Evidence for the involvement of the Ss protein of the mouse in the hemolytic complement system. *J. Exp. Med.* **141**:1216.